111 related articles for article (PubMed ID: 25683936)
1. VEGF Trapon inhibits tumor growth in papillary thyroid carcinoma.
Peng XG; Chen ZF; Zhang KJ; Wang PG; Liu ZM; Chen ZJ; Hou GY; Niu M
Eur Rev Med Pharmacol Sci; 2015; 19(2):235-40. PubMed ID: 25683936
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.
Verheul HM; Hammers H; van Erp K; Wei Y; Sanni T; Salumbides B; Qian DZ; Yancopoulos GD; Pili R
Clin Cancer Res; 2007 Jul; 13(14):4201-8. PubMed ID: 17634549
[TBL] [Abstract][Full Text] [Related]
3. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.
Straight AM; Oakley K; Moores R; Bauer AJ; Patel A; Tuttle RM; Jimeno J; Francis GL
Cancer Chemother Pharmacol; 2006 Jan; 57(1):7-14. PubMed ID: 16001179
[TBL] [Abstract][Full Text] [Related]
4. Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model.
Bauer AJ; Patel A; Terrell R; Doniparthi K; Saji M; Ringel M; Tuttle RM; Francis GL
Ann Clin Lab Sci; 2003; 33(2):192-9. PubMed ID: 12817624
[TBL] [Abstract][Full Text] [Related]
5. The chemokine receptor CXCR7 is a critical regulator for the tumorigenesis and development of papillary thyroid carcinoma by inducing angiogenesis in vitro and in vivo.
Zhang H; Yang L; Teng X; Liu Z; Liu C; Zhang L; Liu Z
Tumour Biol; 2016 Feb; 37(2):2415-23. PubMed ID: 26383519
[TBL] [Abstract][Full Text] [Related]
6. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
[TBL] [Abstract][Full Text] [Related]
7. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas.
Kilicarslan AB; Ogus M; Arici C; Pestereli HE; Cakir M; Karpuzoglu G
APMIS; 2003 Mar; 111(3):439-43. PubMed ID: 12752224
[TBL] [Abstract][Full Text] [Related]
8. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.
Salajegheh A; Pakneshan S; Rahman A; Dolan-Evans E; Zhang S; Kwong E; Gopalan V; Lo CY; Smith RA; Lam AK
Hum Pathol; 2013 Oct; 44(10):2204-12. PubMed ID: 23845470
[TBL] [Abstract][Full Text] [Related]
9. Relationship between preoperative serum TSH levels and expression of VEGF in papillary thyroid carcinoma.
Li J; Teng L; Jiang H
Asia Pac J Clin Oncol; 2014 Jun; 10(2):149-52. PubMed ID: 23718885
[TBL] [Abstract][Full Text] [Related]
10. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
11. Interactive role of miR-126 on VEGF-A and progression of papillary and undifferentiated thyroid carcinoma.
Salajegheh A; Vosgha H; Rahman MA; Amin M; Smith RA; Lam AK
Hum Pathol; 2016 May; 51():75-85. PubMed ID: 27067785
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
[TBL] [Abstract][Full Text] [Related]
13. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
14. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
15. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study.
Schoenberger J; Grimm D; Kossmehl P; Infanger M; Kurth E; Eilles C
Endocrinology; 2004 Mar; 145(3):1031-8. PubMed ID: 14607854
[TBL] [Abstract][Full Text] [Related]
16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
17. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
18. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
19. Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesis.
Scarpino S; D'Alena FC; Di Napoli A; Ballarini F; Prat M; Ruco LP
J Pathol; 2003 Feb; 199(2):243-50. PubMed ID: 12533838
[TBL] [Abstract][Full Text] [Related]
20. Expression of Vascular Endothelial Growth Factor and Its Receptors in Thyroid Nodular Hyperplasia and Papillary Thyroid Carcinoma: A Tertiary Health Care Centre Based Study.
Mohamad Pakarul Razy NH; Wan Abdul Rahman WF; Win TT
Asian Pac J Cancer Prev; 2019 Jan; 20(1):277-282. PubMed ID: 30678450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]